142 filings
8-K
AKBA
Akebia Therapeutics Inc.
9 May 24
Akebia Therapeutics Reports First Quarter 2024 Financial Results
7:03am
8-K
AKBA
Akebia Therapeutics Inc.
23 Apr 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
8:32am
8-K
AKBA
Akebia Therapeutics Inc.
16 Apr 24
Entry into a Material Definitive Agreement
7:33am
8-K
AKBA
Akebia Therapeutics Inc.
27 Mar 24
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
8:35pm
8-K
AKBA
Akebia Therapeutics Inc.
15 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
rdd4lrb
14 Mar 24
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
4:18pm
8-K
dt39v4pff0fjy8y8
13 Feb 24
Departure of Directors or Certain Officers
8:00am
8-K
8srl3l 20nljl
30 Jan 24
Entry into a Material Definitive Agreement
8:05am
8-K
uom6j z9gn
8 Jan 24
Departure of Directors or Certain Officers
4:08pm
8-K
tv0btnujf 3dci
8 Jan 24
Results of Operations and Financial Condition
8:02am
8-K
0zfann
18 Dec 23
Entry into a Material Definitive Agreement
4:07pm
8-K
01ijyl0m7kbmsl9a
21 Nov 23
Other Events
5:07pm
8-K
0xebu vlb6fb2vyeyne
8 Nov 23
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
7:33am
8-K
90beg0e
2 Nov 23
Entry into a Material Definitive Agreement
4:34pm
8-K
h8dl52ty9sj
25 Oct 23
Akebia Receives FDA Acceptance of Resubmission to NDA of
4:06pm
8-K
muym73s
12 Oct 23
Departure of Directors or Certain Officers
8:31am
8-K
fc40798yrc8q1z
26 Sep 23
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
4:47pm
8-K
4si5jub
25 Aug 23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
8:14am
8-K
melsl
17 Aug 23
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
4:09pm
8-K
2djkoszds
11 Aug 23
Akebia Therapeutics Provides Update on Form 10-Q Filing
7:35am